CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 395 enrolled
Drug / intervention
Citalopram +2 moredrug
Likely dose
Citalopram 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01179568
NCT01179568Phase 2Completed

Optimizing Treatment for Complicated Grief (Healing Emotions After Loss:HEAL)

New York State Psychiatric Institute·interventional·Posted Aug 11, 2010·Updated Jan 24, 2017

In Brief

A Phase 2 clinical trial evaluating Citalopram, Complicated Grief Treatment, and 1 other intervention for Complicated Grief and Bereavement. Completed, enrolled 395 participants across 4 sites.

Detailed Summary

The major goal of this 4-site, double blind, placebo-controlled intervention trial is to assess the efficacy of medication (Citalopram) alone or with psychotherapy (Complicated Grief Therapy) to treat the symptoms of complicated grief.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 11, 2010
Enrollment StartMar 1, 2010
Primary CompletionFeb 1, 2015
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 15.9 years ago

Interventions

Citalopramdrug

16 weeks of medication provided flexibly up to 40 mg/day. Medication will be administered in a double-blind fashion.

Complicated Grief Treatmentbehavioral

Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided within 20 weeks.

Placeboother

16 weeks of daily inactive medication. It will be administered in a double-blind fashion.